HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

HX531 is an orally active antagonist of RXR. HX531 enhances activation of the p53–p21Cip1 pathway and abrogates the anti-apoptotic effects of all-trans-retinoic acid (t-RA). HX531 exhibits anti-obesity, anti-diabetic, and anti-melanoma properties.

Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) […]

U-73343 is an inactive analog of U-73122 that acts downstream of phospholipase C and inhibits receptor-mediated phospholipase D (PLD) activation in CHO-CCK_A cells.

AMG PERK 44 is a highly selective and orally active inhibitor of PERK with an IC50 of 6 nM. AMG PERK 44 exhibits 1000-fold and 160-fold selectivity over GCN2 and B-Raf, respectively.

AMG PERK 44 is a highly selective and orally active inhibitor of PERK with an IC50 of 6 nM. AMG PERK 44 exhibits 1000-fold and 160-fold selectivity over GCN2 and B-Raf, respectively.

AMG PERK 44 is a highly selective and orally active inhibitor of PERK with an IC50 of 6 nM. AMG PERK 44 exhibits 1000-fold and 160-fold selectivity over GCN2 and B-Raf, respectively.

AMG PERK 44 is a highly selective and orally active inhibitor of PERK with an IC50 of 6 nM. AMG PERK 44 exhibits 1000-fold and 160-fold selectivity over GCN2 and B-Raf, respectively.